Janssen Search
Search results
First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis
May 09, 2023 United States Late-breaking data from the Phase 3 QUASAR Induction Study show statistically significant and clinically meaningful improvements among ulcerative colitis patients, including bio-naïve patients and those who have experienced ...
Celebrating a New Era in Bladder Cancer Treatment
Celebrating a New Era in Bladder Cancer Treatment As we seek to increase awareness of bladder cancer and the patients we serve, it is important to celebrate the enormous strides we have made in further understanding this disease. Recent scientific ...
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
Feb 20, 2024 United States Biweekly dosing with TECVAYLI ®, the first approved BCMA-targeting bispecific antibody, provides patients with dosing flexibility HORSHAM, Pa., February 20, 2024 – Johnson & Johnson announced today that the U.S. Food and ...
Joining Forces with CEPI To Address Epidemic Threat
Joining Forces with CEPI To Address Epidemic Threat Two years ago, in January 2017, the Janssen Pharmaceutical Companies of Johnson & Johnson was proud to support the launch of the Coalition for Epidemic Preparedness Innovations (CEPI) at the World ...
Value of Medicines
How We Think About Value, Access and Pricing We advance healthy outcomes by ensuring healthcare professionals and patients have access to the information, programs and support they need to achieve the best results possible. At Janssen, we seek medical ...
Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in OS in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate Plus Prednisone
Oct 22, 2023 Spain Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer with BRCA Alterations Treated with Niraparib and ...
Janssen Announces TREMFYA® (guselkumab) Demonstrates Significant Skin Clearance in First-of-its-Kind Prospective, Large-Scale Study Dedicated to People of Color Living with Moderate to Severe Plaque Psoriasis
Oct 20, 2023 United States VISIBLE Cohort A Week 16 topline results achieve co-primary endpoints, demonstrating the well-established efficacy and safety profile of TREMFYA ® across all skin tones In additional datasets, TREMFYA ® demonstrated rapid and ...
Contact Us
Thank you for your interest in learning more about Janssen. We care about your questions and concerns. Adverse Event/Product Quality Complaint Reporting If you would like to report an Adverse Event (medication side effect) and/or Product Quality ...
Congyang (Tom) Wu
CONGYANG (TOM) WU ASIA PACIFIC HEAD WORLD WITHOUT DISEASE ACCELERATOR As Asia Pacific Head, World Without Disease Accelerator (WWDA), Tom is responsible for the overall strategic and executional efforts of the WWDA in Asia Pacific, with an initial focus ...
Why Vaccines are my Vocation
Why Vaccines are my Vocation World Immunization Week (WIW) is recognized during the week of April 24–30. It is a good time to reflect on, and recognize our commitment to, the public health value of vaccination. Sponsored by the World Health Organization ...